BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1852077)

  • 1. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid.
    Skowsky WR; Wilf LH
    South Med J; 1991 May; 84(5):636-41. PubMed ID: 1852077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
    Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
    J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma.
    Hilditch TE; Connell JM; Elliot AT; Murray T; Reed NS
    J Nucl Med; 1986 Jul; 27(7):1150-3. PubMed ID: 3014086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
    Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
    J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.
    Clarke SE; Lazarus CR; Wraight P; Sampson C; Maisey MN
    J Nucl Med; 1988 Jan; 29(1):33-8. PubMed ID: 2826723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Scintigraphy of medullary carcinoma of the thyroid by new radiopharmaceuticals].
    Tada J; Konishi J; Torizuka K; Makimoto K; Miyauchi A
    Rinsho Hoshasen; 1984 Sep; 29(9):1043-4. PubMed ID: 6096600
    [No Abstract]   [Full Text] [Related]  

  • 7. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.
    Clarke SE; Lazarus CR; Edwards S; Murby B; Clarke DG; Roden TM; Fogelman I; Maisey MN
    J Nucl Med; 1987 Dec; 28(12):1820-5. PubMed ID: 3681441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.
    Troncone L; Rufini V; De Rosa G; Testa A
    Henry Ford Hosp Med J; 1989; 37(3-4):178-84. PubMed ID: 2576959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
    Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
    Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
    Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
    Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radionuclide imaging in medullary thyroid carcinoma: evaluation of two new radiopharmaceuticals.
    Clarke SE; Lazarus CR; Maisey MN
    Henry Ford Hosp Med J; 1987; 35(2-3):124-6. PubMed ID: 2826368
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of medullary carcinoma of the thyroid with I-131 MIBG.
    Thomas CC; Cowan RJ; Albertson DA; Cooper MR
    Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.
    Coutris G; Talbot JN; Kabla G; Calmettes C; Milhaud G
    Eur J Nucl Med; 1986; 12(2):77-9. PubMed ID: 3732310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tracers for the imaging of the medullary thyroid carcinoma.
    Guerra UP; Pizzocaro C; Terzi A; Giubbini R; Maira G; Pagliaini R; Bestagno M
    Nucl Med Commun; 1989 Apr; 10(4):285-95. PubMed ID: 2544835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging of recurrent medullary thyroid cancer.
    Simon GH; Nitzsche EU; Laubenberger JJ; Einert A; Moser E
    Nuklearmedizin; 1996 Jun; 35(3):102-4. PubMed ID: 8710526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
    Sone T; Fukunaga M; Otsuka N; Morita R; Muranaka A; Yanagimoto S; Tomomitsu T; Nakayama H; Harada T
    J Nucl Med; 1985 Jun; 26(6):604-8. PubMed ID: 3158726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumour scintigraphy.
    Hirano T; Tomiyoshi K; Zhang YJ; Ishida T; Inoue T; Endo K
    Eur J Nucl Med; 1994 Jan; 21(1):82-5. PubMed ID: 8088289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
    Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
    Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
    Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
    J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma.
    Hoefnagel CA; Delprat CC; Zanin D; van der Schoot JB
    Clin Nucl Med; 1988 Mar; 13(3):159-65. PubMed ID: 2838213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.